Radiation therapy for endometrial cancer after surgery
Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer: A Prospective Phase II Trial (POHIM_EM Trial)
This study tests a new type of radiation therapy for women with stage III endometrial cancer after surgery to see if it helps them stay cancer-free as well as traditional treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 92 (estimated) |
| Ages | 20 Years to 80 Years |
| Sex | Female |
| Sponsor | Samsung Medical Center Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Seoul) |
| Trial ID | NCT05876130 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of hypofractionated intensity-modulated whole pelvic radiation therapy in women with stage III endometrial cancer who have undergone curative surgery. The focus is on determining whether this treatment approach can achieve non-inferior disease-free survival compared to traditional methods. Participants will receive a specific radiation dose over a set number of fractions following their surgery. The study aims to provide insights into optimizing postoperative care for this patient population.
Who should consider this trial
Good fit: Ideal candidates are women with histologically confirmed endometrioid type endometrial cancer who have completed surgery and are at FIGO stage III.
Not a fit: Patients with distant metastasis or those who have had previous pelvic radiotherapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve disease-free survival rates for women with stage III endometrial cancer after surgery.
How similar studies have performed: Other studies have shown promise with hypofractionated radiation therapy in various cancers, suggesting potential for success in this approach for endometrial cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * histologically confirmed endometrioid type endometrial cancer * completion of hysterectomy and surgical staging * pathologically confirmed FIGO stage III * ECOG performance status 0 or 1 * adjuvant chemotherapy was done or planned Exclusion Criteria: * presence of distant metastasis * previous history of pelvic radiotherapy * severe and unstable medical condition * previous history of other carcinoma except for thyroid cancer, skin cancer, and endometrial cancer
Where this trial is running
Seoul
- Samsung Medical Center — Seoul, South Korea (Recruiting)
Study contacts
- Principal investigator: Won Park — Samsung Medical Center
- Study coordinator: Won Park
- Email: wonro.park@samsung.com
- Phone: +82-2-3410-2612
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.